Medicamen Biotech Ltd.
Snapshot View

834.65 -15.40 ▼-1.8%

02 December 2022, 04:01:00 PM
Volume: 1,018

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.medicamen.com
Market Cap 1,065.48 Cr.
Enterprise Value(EV) 1,053.86 Cr. 2022-09
Financial Indicators
Earnings per share (EPS) 10.84 Trailing Twelve Months Ending 2022-09
Price-Earning Ratio (PE) 77.00 Trailing Twelve Months Ending 2022-09
Industry PE 35.40 Trailing Twelve Months Ending 2022-09
Book Value / Share 139.69 Trailing Twelve Months Ending 2022-09
Price to Book Value 5.97 Calculated using Price: 834.65
Dividend Yield 0.12 Period Ending 2022-03
No. of Shares Subscribed 1.27 Cr. 12,651,100 Shares
FaceValue 10
Company Profile
Medicamen Biotech Limited was incorporated in December 1993, it is a widely held, Globaly Recognized public limited company engaged in manufacturing and marketing of pharmaceutical formulations in overseas and domestic markets. Medicamen Biotech Limited is committed to produce and provide quality medicines at competitive price for domestic as well as international markets thereby being socially responsible and rendering services to the medical fraternity since inception.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
-1.81%
1 Week
-3.27%
1 Month
-1.07%
3 Month
-26.76%
6 Month
+17.96%
1 Year
+39.19%
2 Year
+113.82%
5 Year
+32.54%
10 Year
+6360.14%
4 years 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 13.95 12.94 9.89 11.24
Return on Capital Employed (%) 19.30 16.54 12.99 12.94
Return on Assets (%) 8.80 8.36 6.46 7.11

Balance Sheet View Details >>

Particulars 5 years 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09* Rs. Cr.
Shh. Funds 87 121 133 146 186
Non Curr. Liab. 1 4 8 6 2
Curr. Liab. 49 56 53 73 70
Minority Int.
Equity & Liab. 137 181 194 225 258
Non Curr. Assets 40 75 91 94 105
Curr. Assets 96 104 96 123 153
Misc. Exp. not W/O 0 2 7 8
Total Assets 137 181 194 225 258

Profit Loss View Details >>

Particulars 5 years 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09 Rs. Cr. TTM
Net Sales 123 126 113 115 122
Other Income 4 2 1 2 3
Total Income 126 127 113 117 125
Total Expenditure -105 -106 -93 -91 -99
PBIDT 21 21 20 26 25
Interest -1 -1 -2 -2 -2
Depreciation -2 -3 -3 -6 -6
Taxation -6 -5 -4 -3 -3
Exceptional Items
PAT 12 13 12 15 14
Minority Interest
Share Associate
Other Related Items
Consolidated Net Profit 12 13 12 15 14
Adjusted EPS 10 11 10 12 11

Cash Flow View Details >>

Particulars 4 years 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 4 13 13 4
Cash Fr. Inv. -15 -37 -18 -8
Cash Fr. Finan. -4 19 6 4
Net Change -14 -5 1 0
Cash & Cash Eqvt 9 3 4 4

Shareholding Pattern View Details >>

9 Qtrs 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%)
Promoter 44.77 44.77 44.83 44.83 44.83 43.60 43.60 43.60 43.21
Public 55.23 55.23 55.17 55.17 55.17 56.40 56.40 56.40 56.79
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details >>

Wed, 23 Nov 2022
Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015
Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed herewith details of related party transactions on consolidated basis for the half year ended on September 30 2022.You are requested to take the same on record.
Tue, 15 Nov 2022
Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to regulation 30 & 47 of SEBI (Listing obligation and disclosure requirements) Regulations 2015 (the Regulations) please find enclosed newspaper cutting with regard to the publication of extract of Un-Audited Financial Results of the Company for the quarter and half year ended on September 30 2022 approved by the Board of Directors at their Meeting held on 11.11.2022.The copy of the results published in the Financial Express and Jansatta dated November 12 2022 is enclosed.This is for your information and records.Kindly acknowledge the receipt.
Fri, 11 Nov 2022
Unaudited Financial Results For The Quarter Ended On September 30 2022
We wish to inform you that the Board of Directors of the Company at its meeting held today approved the Un-Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended on September 30 2022.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we enclose the following:

a) Statement showing the Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended on September 30 2022 as Annexure-A and
b) Limited Review Report from Rai Qimat & Associates Chartered Accountants on the Un- Audited Financial Results (Standalone & Consolidated) as Annexure-B
c) An Investor release on the financial results is enclosed as Annexure-C

The meeting of the Board of Directors commenced on 02.30 p.m. and concluded at 03.30 p.m.

Technical Scans View Details >>

Fri, 02 Dec 2022
Higher Delivery Quantity Higher Delivery Quantity
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity
High Decrease 3 Months High Decrease 3 Months
High Increase 1 Year High Increase 1 Year

Related Stocks View Details >>

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 249,530.84 1,040.00 -0.6%
Cipla Ltd. 89,936.23 1,114.35 -0.9%
Divi's Laboratories Ltd. 89,761.56 3,381.25 -0.8%
Dr. Reddy's Laboratories Ltd. 75,098.21 4,510.40 +0.8%
Apollo Hospitals Enterprise Ltd. 70,043.98 4,871.45 +2.0%
Torrent Pharmaceuticals Ltd. 54,931.39 1,623.05 -1.2%
Max Healthcare Institute Ltd. 43,491.25 448.10 -0.9%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-09 60.50 1,040.00 -0.6%
Cipla Ltd. Consolidated 2022-09 35.23 1,114.35 -0.9%
Divi's Laboratories Ltd. Consolidated 2022-09 29.99 3,381.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-09 24.23 4,510.40 +0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 83.18 4,871.45 +2.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-09 68.92 1,623.05 -1.2%
Max Healthcare Institute Ltd. Consolidated 2022-09 46.09 448.10 -0.9%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-09 4.68 1,040.00 -0.6%
Cipla Ltd. Consolidated 2022-09 4.13 1,114.35 -0.9%
Divi's Laboratories Ltd. Consolidated 2022-09 7.40 3,381.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-09 3.63 4,510.40 +0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 11.67 4,871.45 +2.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-09 9.02 1,623.05 -1.2%
Max Healthcare Institute Ltd. Consolidated 2022-09 6.29 448.10 -0.9%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.02 1,040.00 -0.6%
Cipla Ltd. Consolidated 2022-03 0.04 1,114.35 -0.9%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 3,381.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,510.40 +0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,871.45 +2.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,623.05 -1.2%
Max Healthcare Institute Ltd. Consolidated 2022-03 0.12 448.10 -0.9%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,040.00 -0.6%
Cipla Ltd. Consolidated 2022-03 13.10 1,114.35 -0.9%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,381.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,510.40 +0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,871.45 +2.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,623.05 -1.2%
Max Healthcare Institute Ltd. Consolidated 2022-03 10.19 448.10 -0.9%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,040.00 -0.6%
Cipla Ltd. Consolidated 2022-03 13.10 1,114.35 -0.9%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,381.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,510.40 +0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,871.45 +2.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,623.05 -1.2%
Max Healthcare Institute Ltd. Consolidated 2022-03 10.19 448.10 -0.9%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 1,040.00 -0.6%
Cipla Ltd. Consolidated 2022-03 21,763.34 1,114.35 -0.9%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 3,381.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,510.40 +0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,871.45 +2.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,623.05 -1.2%
Max Healthcare Institute Ltd. Consolidated 2022-03 3,931.46 448.10 -0.9%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 1,040.00 -0.6%
Cipla Ltd. Consolidated 2022-03 2,559.47 1,114.35 -0.9%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 3,381.25 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,112.20 4,510.40 +0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,871.45 +2.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,623.05 -1.2%
Max Healthcare Institute Ltd. Consolidated 2022-03 605.05 448.10 -0.9%

FAQ's On Medicamen Biotech Ltd.

What is Medicamen Biotech share price?

Can I buy Medicamen Biotech shares now?

What is the Dividend Yield of Medicamen Biotech?

What is the Market Cap of Medicamen Biotech?

What are the key metrics to analyse Medicamen Biotech?

What is the 52 Week High and Low of Medicamen Biotech?

What is the trend of Medicamen Biotech share price?